VRTX · News · 20260814N

Acquisition / Partnership / Divestiture

VERTEX PHARMACEUTICALS INC / MA · 2026-08-14 · Importance 71 · Surprise 60 · In source text

Vertex announced an approximately $10 billion acquisition of Crinetics Pharmaceuticals on July 6, 2026. The transaction is intended to strengthen Vertex’s position in endocrinology drugs. The merger received HSR clearance after the waiting period expired on August 12, 2026, and obtained antitrust approvals in Austria, Germany, and Australia. Closing is targeted for early September 2026, subject to Crinetics shareholder approval at a special meeting scheduled for August 28, 2026.

Key facts

• On July 6, Vertex announced the acquisition of Crinetics Pharmaceuticals for about $10 billion. source
• A special meeting for Crinetics shareholders to consider the merger with Vertex is scheduled for August 28, 2026. source
• The proposed merger between Crinetics Pharmaceuticals and Vertex has progressed after securing regulatory clearances including the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period and approvals in Austria, Germany, and Australia. source
• The HSR waiting period for the Crinetics merger expired on August 12, 2026. source

Impact estimates